Javascript must be enabled to continue!
Increasing rates of screening and treatment of iron deficiency in ambulatory patients with heart failure with reduced ejection fraction: a quality improvement cohort study
View through CrossRef
Introduction
Iron deficiency anaemia (IDA) is common in patients with heart failure (HF) and is associated with advanced HF and increased mortality. Intravenous iron supplementation increases exercise tolerance, improves quality of life, and decreases symptoms among patients with HF with reduced ejection fraction (HFrEF) and iron deficiency. Despite this, many patients are not screened or treated for IDA. We aimed to increase rates of screening and treatment of IDA among HF patients through the introduction of curated materials to aid HF clinicians with appropriate screening and treatment.
Methods
We conducted a retrospective chart review to identify the baseline number of HFrEF patients screened and treated for IDA at two ambulatory cardiology clinics in Toronto, Ontario. A quality improvement initiative was then introduced, which consisted of education and curated materials to aid clinicians in the screening and treatment of IDA among HFrEF patients. The proportion of patients screened and treated for IDA preintervention and postintervention were compared using χ2 tests of Independence.
Results
In the preintervention cohort, 36.3% (n=45) of patients with anaemia were screened for IDA. Among those screened, 64.4% (n=29) had IDA. Only 17.2% (n=5) of these were treated with IV iron. After implementation of the quality improvement initiative, 90.9% (n=60) of patients with anaemia were screened for IDA (p<0.001) and 90.3% (n=28) of those with IDA were treated with IV iron (p<0.001).
Conclusion
The introduction of curated materials to aid clinicians was associated with increased rates of screening and treatment of IDA among ambulatory HFrEF patients. Further work is required to identify barriers and implement strategies to increase screening and treatment rates of IDA among HFrEF patients.
Title: Increasing rates of screening and treatment of iron deficiency in ambulatory patients with heart failure with reduced ejection fraction: a quality improvement cohort study
Description:
Introduction
Iron deficiency anaemia (IDA) is common in patients with heart failure (HF) and is associated with advanced HF and increased mortality.
Intravenous iron supplementation increases exercise tolerance, improves quality of life, and decreases symptoms among patients with HF with reduced ejection fraction (HFrEF) and iron deficiency.
Despite this, many patients are not screened or treated for IDA.
We aimed to increase rates of screening and treatment of IDA among HF patients through the introduction of curated materials to aid HF clinicians with appropriate screening and treatment.
Methods
We conducted a retrospective chart review to identify the baseline number of HFrEF patients screened and treated for IDA at two ambulatory cardiology clinics in Toronto, Ontario.
A quality improvement initiative was then introduced, which consisted of education and curated materials to aid clinicians in the screening and treatment of IDA among HFrEF patients.
The proportion of patients screened and treated for IDA preintervention and postintervention were compared using χ2 tests of Independence.
Results
In the preintervention cohort, 36.
3% (n=45) of patients with anaemia were screened for IDA.
Among those screened, 64.
4% (n=29) had IDA.
Only 17.
2% (n=5) of these were treated with IV iron.
After implementation of the quality improvement initiative, 90.
9% (n=60) of patients with anaemia were screened for IDA (p<0.
001) and 90.
3% (n=28) of those with IDA were treated with IV iron (p<0.
001).
Conclusion
The introduction of curated materials to aid clinicians was associated with increased rates of screening and treatment of IDA among ambulatory HFrEF patients.
Further work is required to identify barriers and implement strategies to increase screening and treatment rates of IDA among HFrEF patients.
Related Results
Prevalence of Iron Deficiency in Patients of Heart Failure with Reduced Ejection Fraction and Response to Injectable Iron Therapy- A Hospital Based Observational Study
Prevalence of Iron Deficiency in Patients of Heart Failure with Reduced Ejection Fraction and Response to Injectable Iron Therapy- A Hospital Based Observational Study
Aim of the Study: To estimate the prevalence of iron deficiency in patients of heart failure with reduced ejection fraction & response to injectable iron therapy in patients wi...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Background: Heart failure with reduced ejection fraction is a major cause of morbidity, hospital admission, and cardiovascular mortality worldwide. Many patients end up with poor f...
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Abstract
Background: Comorbidities and sex differences play a major role in chronic heart failure (CHF). However, it is unknown whether the prevalence of comorbidities diff...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
VITAMIN D INSUFFICIENCY IN FOUR MAJOR HOSPITALS OF PUNJAB
VITAMIN D INSUFFICIENCY IN FOUR MAJOR HOSPITALS OF PUNJAB
Objective: To demonstrate vitamin D deficiency in the general population of Punjab
Study Design: Observational, Cross-Sectional
Place and Duration: Multicentre study co...
Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study
Treatment outcomes and associated factors among chronic ambulatory heart failure patients at Jimma Medical Center, South West Ethiopia: prospective observational study
Abstract
Background
Heart failure has been one of the major causes of hospitalization across the world. Focusing on the treatment outcomes of ambula...

